A Study of LY317615 in Patients With Brain Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00190723|
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : January 26, 2007
- The safety of LY317615 and any side effects that might be associated with the drug.
- Whether LY317615, can help patients with brain tumors.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Glioma||Drug: Enzastaurin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas|
|Study Start Date :||October 2002|
|Estimated Study Completion Date :||December 2006|
- To establish data regarding the anti-tumor activity of LY317615 in patients with recurrent high-grade gliomas.
- To obtain preliminary information regarding the spectrum of toxicities of LY317615 administered to patients with recurrent high-grade gliomas
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00190723
|United States, Maryland|
|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician|
|Bethesda, Maryland, United States, 20892|
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)||Eli Lilly and Company|